Principal Securities’s Gyre Therapeutics GYRE Stock Holding History

Principal Securities’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-85	Closed	-$634	–	2265
2025 Q3	$634	Hold	85	–	–	﹤0.01%	3493
2025 Q2	$625	Buy	+85	New	+$742	﹤0.01%	3442

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Securities's GYRE Position: Q4 2025 in Review

Principal Securities sold out of Gyre Therapeutics (GYRE) in Q4 2025, closing a stake of 85 shares — an estimated $634 sold.

Principal Securities first reported a position in GYRE in Q2 2025 and held it in 2 quarters. The position peaked at $634 in Q3 2025. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.

Principal Securities reported no remaining Gyre Therapeutics position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 85 Gyre Therapeutics shares in Q4 2025, an estimated $634.
Principal Securities first reported a position in Gyre Therapeutics in Q2 2025 and held it in 2 quarters.
Principal Securities's Gyre Therapeutics position peaked at $634 in Q3 2025.
44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.